US Stock MarketDetailed Quotes
MRNS Marinus Pharmaceuticals
- 1.260
- +0.040+3.28%
Close Aug 16 16:00 ET
- 1.260
- 0.0000.00%
Post 20:01 ET
69.41MMarket Cap-473P/E (TTM)
1.280High1.200Low303.45KVolume1.200Open1.220Pre Close380.47KTurnover0.80%Turnover RatioLossP/E (Static)55.08MShares11.26052wk High-1.47P/B47.99MFloat Cap1.05052wk Low--Dividend TTM38.09MShs Float82.880Historical High--Div YieldTTM6.56%Amplitude1.050Historical Low1.253Avg Price1Lot Size
Marinus Pharmaceuticals Key Stats
Quarterly+Annual
YOY
| (Q2)Jun 30, 2024 | (Q1)Mar 31, 2024 | (FY)Dec 31, 2023 | (Q4)Dec 31, 2023 | (Q3)Sep 30, 2023 | (Q2)Jun 30, 2023 | (Q1)Mar 31, 2023 | (FY)Dec 31, 2022 | (Q4)Dec 31, 2022 | (Q3)Sep 30, 2022 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total revenue | 32.48%8.06M | -26.02%7.68M | 21.63%30.99M | 0.39%7.19M | 213.59%7.34M | 239.72%6.08M | -26.83%10.38M | 66.03%25.48M | 371.18%7.16M | -76.86%2.34M |
| Operating revenue | 32.48%8.06M | -26.02%7.68M | 21.63%30.99M | 0.39%7.19M | 213.59%7.34M | 239.72%6.08M | -26.83%10.38M | 66.03%25.48M | 371.18%7.16M | -76.86%2.34M |
| Cost of revenue | 90.41%735K | 266.99%756K | 468.82%1.93M | 203.77%887K | 847.92%455K | 386K | 206K | -77.00%340K | 292K | -96.75%48K |
| Gross profit | 28.55%7.32M | -31.95%6.92M | 15.58%29.06M | -8.25%6.3M | 200.31%6.88M | 218.16%5.7M | -28.28%10.17M | 81.28%25.14M | 351.97%6.87M | -73.46%2.29M |
| Operating expense | 1.27%37.61M | -0.91%42.74M | 16.40%160.54M | 15.68%41.74M | 18.95%38.53M | -3.69%37.13M | 39.62%43.14M | 24.48%137.93M | 26.00%36.08M | 16.49%32.39M |
| Selling and administrative expenses | 6.28%16.71M | 22.51%18.63M | 7.58%61.15M | 4.78%15.36M | 11.05%14.87M | -7.85%15.72M | 29.54%15.2M | 52.49%56.85M | 38.00%14.66M | 41.65%13.39M |
| Research and development costs | -2.41%20.9M | -13.66%24.12M | 24.37%99.39M | 23.14%26.38M | 24.52%23.66M | -0.39%21.41M | 55.26%27.93M | 8.69%79.91M | 18.93%21.42M | 3.54%19M |
| Other operating expenses | ---- | ---- | ---- | ---- | ---- | ---- | ---- | --1.17M | --0 | ---- |
| Operating profit | 3.67%-30.29M | -8.67%-35.82M | -16.58%-131.49M | -21.31%-35.44M | -5.14%-31.65M | 14.49%-31.44M | -97.25%-32.96M | -16.36%-112.79M | -7.73%-29.21M | -57.02%-30.1M |
| Net non-operating interest income expense | -68.65%-3.51M | -59.87%-2.88M | -5.58%-8.78M | -31.09%-2.55M | -10.71%-2.35M | 19.13%-2.08M | -7.38%-1.8M | -232.45%-8.32M | -27.19%-1.95M | -220.73%-2.12M |
| Non-operating interest income | -47.89%1.11M | -37.60%1.46M | 244.65%8.11M | 0.17%1.75M | 268.68%1.9M | 2,433.33%2.13M | 19,425.00%2.34M | 2,842.50%2.35M | 7,482.61%1.74M | 2,923.53%514K |
| Non-operating interest expense | 9.72%4.62M | 4.80%4.35M | 58.31%16.9M | 16.48%4.3M | 61.05%4.24M | 58.43%4.21M | 145.09%4.15M | 313.32%10.67M | 137.60%3.69M | 288.50%2.63M |
| Other net income (expense) | -4,427.66%-2.03M | -2.70%36K | -102.56%-2.68M | -149.24%-3.78M | -99.05%1.02M | 149.47%47K | 103.81%37K | 15,832.88%104.68M | -544.87%-1.52M | 33,107.74%107.26M |
| Special income (charges) | ---1.95M | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
| -Less：Restructuring and merger&acquisition | --1.95M | ---- | ---- | ---- | ---- | --0 | ---- | ---- | ---- | ---- |
| Other non- operating income (expenses) | -278.72%-84K | -2.70%36K | -102.56%-2.68M | -149.24%-3.78M | -99.05%1.02M | 149.47%47K | 103.81%37K | 15,832.88%104.68M | -544.87%-1.52M | 33,107.74%107.26M |
| Income before tax | -7.04%-35.83M | -11.34%-38.67M | -770.17%-142.94M | -27.83%-41.77M | -143.94%-32.97M | 15.12%-33.47M | -79.38%-34.73M | 83.37%-16.43M | -15.44%-32.68M | 484.69%75.04M |
| Income tax | 0 | -145.38%-1.54M | 0 | 0 | -1.54M | 3.39M | 1.64M | 1.75M | ||
| Net income | -12.19%-35.83M | -11.34%-38.67M | -613.59%-141.41M | -21.73%-41.77M | -144.99%-32.97M | 19.02%-31.93M | -79.38%-34.73M | 79.94%-19.82M | -21.22%-34.31M | 475.71%73.29M |
| Net income continuous Operations | -12.19%-35.83M | -11.34%-38.67M | -613.59%-141.41M | -21.73%-41.77M | -144.99%-32.97M | 19.02%-31.93M | -79.38%-34.73M | 79.94%-19.82M | -21.22%-34.31M | 475.71%73.29M |
| Minority interest income | ||||||||||
| Net income attributable to the parent company | -12.19%-35.83M | -11.34%-38.67M | -613.59%-141.41M | -21.73%-41.77M | -144.99%-32.97M | 19.02%-31.93M | -79.38%-34.73M | 79.94%-19.82M | -21.22%-34.31M | 475.71%73.29M |
| Preferred stock dividends | 1.66M | |||||||||
| Other preferred stock dividends | ||||||||||
| Net income attributable to common stockholders | -12.19%-35.83M | -11.34%-38.67M | -613.59%-141.41M | -22.94%-41.77M | -146.03%-32.97M | 19.02%-31.93M | -79.38%-34.73M | 79.94%-19.82M | -20.04%-33.98M | 467.22%71.63M |
| Basic earnings per share | -3.28%-0.63 | -1.49%-0.68 | -415.69%-2.63 | 2.63%-0.74 | -131.61%-0.61 | 42.45%-0.61 | -28.85%-0.67 | 81.04%-0.51 | 1.30%-0.76 | 464.15%1.93 |
| Diluted earnings per share | -3.28%-0.63 | -1.49%-0.68 | -415.69%-2.63 | 2.63%-0.74 | -132.28%-0.61 | 42.45%-0.61 | -28.85%-0.67 | 81.04%-0.51 | 1.30%-0.76 | 456.60%1.89 |
| Dividend per share | ||||||||||
| Currency Unit | USD | USD | USD | USD | USD | USD | USD | USD | USD | USD |
| Accounting Standards | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP | US-GAAP |
| Audit Opinions | -- | -- | Unqualified Opinion with Explanatory Notes | -- | -- | -- | -- | Unqualified Opinion | -- | -- |
Analysis
Price Target
No Data
Heat List
US
Overall
Symbol
Latest Price
% Chg